ArticleBiomedicines2021
Antimicrobial, Immunomodulatory and Anti-Inflammatory Potential of Liposomal Thymoquinone: Implications in the Treatment of Bacterial Pneumonia in Immunocompromised Mice.
Article in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Antibacterial and Immunomodulatory Effects ofInternational journal of molecular sciences · 2026Article
- Liposomal Methylglyoxal Targets Virulence and Intracellular Persistence to Overcome Amphotericin B Resistance inInternational journal of molecular sciences · 2026Article
- Article
- Liposome drug delivery strategies: state-of-the-art for combating bacterial biofilms.Frontiers in microbiology · 2026Review
- Exploring Molecular Mechanism of Thymoquinone via cMet and PDGFR for Accelerated Hemostasis: An Approach Through In Silico, In Vitro, and In Vivo Studies.Chemistry & biodiversity · 2026Article
- Analysis of Pharmacological Properties ofLife (Basel, Switzerland) · 2025Review
- Thymoquinone-conjugated liposomes improve cytotoxic and proapoptotic effects against hepatocellular cancer by altering the EGFR/ERK/MEK signaling axis.Discover oncology · 2025Article
- Enhanced activity of Ellagic acid in lipid nanoparticles (EA-liposomes) againstSaudi journal of biological sciences · 2023Article
- Liposomes-Based Drug Delivery Systems of Anti-Biofilm Agents to Combat Bacterial Biofilm Formation.Antibiotics (Basel, Switzerland) · 2023Review
- Natural Bioactive Compounds Targeting NADPH Oxidase Pathway in Cardiovascular Diseases.Molecules (Basel, Switzerland) · 2023Review
- Nanomaterials for Delivering Antibiotics in the Therapy of Pneumonia.International journal of molecular sciences · 2022Review
- The significance of thymoquinone administration on liver toxicity of diazinon and cholinesterase activity; a recommendation for prophylaxis among individuals at risk.BMC complementary medicine and therapies · 2022Article
- Glycosphingolipids (GSLs) fromMolecules (Basel, Switzerland) · 2022Article
- Editorial for the Specific Issue: "Lipid-Based Nanocarriers".Biomedicines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.